OSSEOFLEX SB INFLATABLE BONE TAMP

K122533 · Osseon Therapeutics, Inc. · NDN · Oct 23, 2012 · Orthopedic

Device Facts

• Record ID: K122533
• Device Name: OSSEOFLEX SB INFLATABLE BONE TAMP
• Applicant: Osseon Therapeutics, Inc.
• Product Code: NDN · Orthopedic
• Decision Date: Oct 23, 2012
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3027
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Osseoflex® SB is intended to be used for the reduction and fixation of fractures and/or creation of a void in cancellous bone in the spine. This includes use during percutaneous vertebral augmentation. This system is to be used with cleared spinal polymethymethacrylate (PMMA) bone cements for use during percutaneous vertebral augmentation, such as kyphoplasty.

Device Story

Osseoflex® SB is an inflatable bone tamp used in percutaneous vertebral augmentation (kyphoplasty). The device consists of a balloon catheter that follows a pre-existing access channel in the vertebral body. A steering mechanism, controlled by a knob, allows the clinician to direct the distal end of the device. Under fluoroscopic guidance, the balloon is inflated with a 60% contrast medium to create a cavity and reduce the fracture. Once the void is created, the balloon is deflated and removed, and cleared PMMA bone cement is injected through an Osseoflex® needle to stabilize the fracture. The device is operated by a physician in a clinical setting. It benefits patients by restoring vertebral height and providing structural fixation for spinal fractures.

Clinical Evidence

No clinical data were conducted for this submission; substantial equivalence is supported by non-clinical bench testing.

Technological Characteristics

The device is an 8G steerable balloon catheter featuring a polyurethane balloon. It operates via hydraulic inflation using 60% contrast medium up to 400 psi (27 ATM) and 4ml volume. The device includes a mechanical steering knob for distal tip articulation. It is a single-use, sterile device designed for use with fluoroscopic imaging. No software or electronic components are present.

Indications for Use

Indicated for patients requiring percutaneous vertebral augmentation for the reduction and fixation of spinal cancellous bone fractures and/or creation of a void in the vertebral body.

Regulatory Classification

Identification

Polymethylmethacrylate (PMMA) bone cement is a device intended to be implanted that is made from methylmethacrylate, polymethylmethacrylate, esters of methacrylic acid, or copolymers containing polymethylmethacrylate and polystyrene. The device is intended for use in arthroplastic procedures of the hip, knee, and other joints for the fixation of polymer or metallic prosthetic implants to living bone.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Polymethylmethacrylate (PMMA) Bone Cement.”

Predicate Devices

• Kyphon Inflatable Bone Tamp (K041454, K032212, K010246, K981251)
• CareFusion Inflatable Bone Tamp (K103064, K093463, K090211)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo for "OSSON THERAPEUTICS". The logo is in a stylized font, with each letter outlined in black. The word "THERAPEUTICS" is written in smaller letters below the main logo. The logo has a simple, clean design.

# OCT 2 3 2012

#### 510(k) SUMMARY

A summary of 510(k) safety and effectiveness information in accordance with 21 CFR 807.92.

## 510(k) Owner

Osseon® Therapeutics, Inc. 2330 Circadian Way Santa Rosa, CA 95407 Phone: [phone] Fax: [phone]

### Official Contact

Keith Burger Director of Research and Development

#### Device Information

| Trade or Proprietary<br>Name: | Osseoflex® SB |
|------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Common Name: | Inflatable Bone Tamp |
| Classification Name: | Primary: Arthroscope<br>Secondary: Cement, Bone Vertebroplasty |
| Classification Panel: | Orthopedic |
| Regulation: | Class II per 21CFR §888.1100, Procode HRX<br>Class II per 21CFR §888.3027. Procode NDN |
| Product Code(s) | OF-0005 |
| Legally marketed device(s)<br>to which equivalence is<br>claimed | Kyphon Inflatable Bone Tamp, K041454, K032212, K010246, K981251<br>CareFusion Inflatable Bone Tamp, K103064, K093463, K090211 |
| Reason for 510(k) | New Device |
| Device Description | The Osseoflex® SB is designed for use in balloon kyphoplasty. The<br>balloon serves to create a cavity in the vertebral body, thereby reducing the<br>fracture while still allowing for cement interdigitation. The balloon catheter<br>is the functional part of the device that creates a cavity and reduces the<br>fracture. The balloon catheter provides a conduit through which the<br>physician can inflate the balloon at the distal end of the catheter. After the<br>bone is disrupted, PMMA is injected through an Osseoflex® needle to fill<br>the previously created void(s).<br><br>An access channel is required for Osseoflex® SB placement. The<br>Osseoflex® SB device does not create an access channel; the Osseoflex® SB<br>is designed to follow a pre-existing channel created by an access channel<br>device. The articulating or steering feature of the device assists the clinician<br>in directing the device to the pre-existing channel. The Osseoflex® SB knob<br>can be turned clockwise to aid in directing the distal portion of the device.<br>Turning the knob counter-clockwise will relax the device and allow the |

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows the logo for OSSEON Therapeutics. The logo is in a stylized font, with the letters "OSSEON" in a rounded, sans-serif typeface. Below the main logo, the word "THERAPEUTICS" is written in a smaller, sans-serif font. The logo appears to be a black and white image.

device to be returned to its start position. The device should be manipulated only while under fluoroscopic observation with radiographic equipment that provides high quality images.

Intended Use

The Osseoflex® SB is intended to be used for the reduction and fixation of fractures and/or creation of a void in cancellous bone in the spine. This includes use during percutaneous vertebral augmentation. This system is to be used with cleared spinal polymethymethacrylate (PMMA) bone cements for use during percutaneous vertebral augmentation, such as kyphoplasty.

| Summary of Technological Characteristics of the Device Compared to the Predicate Devices | | | |
|------------------------------------------------------------------------------------------|------------------|-------------------------------------------------------|--------------------------------------------------------------------------|
| Characteristic | New Device | Predicate Device | |
| Trade Name | Osseoflex SB | Kyphon IBT (K041454,<br>K032212, K010246,<br>K981251) | Carefusion<br>AVAmax Vertebral<br>Balloon (K103064,<br>K093463, K090211) |
| Cannula size | 8G | 8G | 8G |
| Balloon Inflation<br>Medium | 60% Contrast | 60% Contrast | 60% Contrast |
| Balloon Material | Polyurethane | Polyurethane | Polyurethane |
| Balloon Size | 15mm | 10, 15, and 20mm | 10, 15, and 20mm |
| 15mm Balloon Diameter<br>at nominal volume (2ml) | 10.2mm | 8.5mm | 11.8mm |
| 15mm 'Balloon Length<br>at nominal volume (2ml) | 13.7mm | 14.6mm | 14.9mm |
| Balloon Shape | Cylindrical | Variable | Cylindrical |
| Max inflation pressure | 400 psi (27 ATM) | 400 psi (27 ATM) | 400 psi (27 ATM) |
| Max inflation volume | 4ml | 4ml | 4ml |

Summary of Non-Clinical Tests Conducted for Determination of Substantial Equivalence Toct Summa Douts C

| Performance Test Summary – Osseoflex SB | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Characteristic | Standard/ Test/<br>FDA Guidance | Results Summary |
| Inflation Pressure | Constrained Burst<br>Test | The balloon catheter exceeded the requirements for<br>the minimum burst pressure in a constrained<br>environment |
| Inflation Volume | Unconstrained<br>Burst Test | The balloon catheter exceeded the requirements for<br>the minimum burst volume in an unconstrained<br>environment |
| Balloon Double<br>Wall Thickness | Calibrated<br>Measurement | The double wall thickness of the balloon was<br>substantially equivalent to that of the predicate devices |
| Summary of Clinical Tests Conducted for Determination of Substantial Equivalence | | |
| N/A – No clinical test were conducted for this submission | | |
| Conclusions Drawn from Non-Clinical and Clinical Data | | |
| The results of the non-clinical tests show that the Osseoflex SB meet or exceed all performance<br>requirements and are substantially equivalent to the predicate devices | | |

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the bird.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

Osseon® Therapeutics, Incorporated % Mr. Keith Burger Director of Research and Development 2330 Circadian Way Santa Rosa, California 95407

Re: K122533

Trade/Device Name: Osseoflex® SB Regulation Number: 21 CFR 888.3027 Regulation Name: Polymethylmethacrylate (PMMA) bone cement Regulatory Class: Class II Product Code: NDN, HRX Dated: October 5, 2012 Received: October 11, 2012

Dear Mr. Burger:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

OCT
23 2012

{3}------------------------------------------------

# Page 2 -- Mr. Keith Burger

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

David Krone

Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for CSSON Therapeutics. The logo is made up of stylized letters that are all uppercase. The word "THERAPEUTICS" is written in smaller letters below the logo.

#### INDICATION FOR USE STATEMENT 12.0

K122533 510 (k) Number:

Osseoflex® SB Device Name:

Indication For Use:

The Osseoflex® SB is intended to be used for the reduction and fixation of fractures and/or creation of a void in cancellous bone in the spine. This includes use during percutaneous vertebral augmentation. The system is to be used with cleared spinal polymethylmethacrylate (PMMA) bone cements indicated for use during percutaneous vertebral augmentation, such as kyphoplasty.

Prescription Use X (Per 21 CFR 801.109)

OR

Over-The-Counter Use

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Division Sign-Off

(Division Sign-Om Division of Surgical, Ofthopedic, and Restorative Devices

510(k) Number K122533

Osseon Therapeutics Incorporated Osseoflex® SB Steerable Bone Tamp 510(k) — K122533